A new-drug application was filed with the FDA by Janssen Biotech for apalutamide, which is being developed as a treatment for men with nonmetastatic castration-resistant prostate cancer. A late-stage study showed a statistically significantly extension of metastasis-free survival in patients who use apalutamide versus placebo.
Janssen seeks FDA approval of prostate cancer drug
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.